AlphaQuest’s Corvus Pharmaceuticals CRVS Stock Holding History

AlphaQuest’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,972	Closed	-$277K	–	490
2025 Q4	$277K	Buy	+35,972	New	+$284K	0.02%	1259

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AlphaQuest's CRVS Position: Q1 2026 in Review

AlphaQuest sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 35,972 shares — an estimated $277K sold.

AlphaQuest first reported a position in CRVS in Q4 2025 and held it in 1 quarter. The position peaked at $277K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

AlphaQuest reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 35,972 Corvus Pharmaceuticals shares in Q1 2026, an estimated $277K.
AlphaQuest first reported a position in Corvus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
AlphaQuest's Corvus Pharmaceuticals position peaked at $277K in Q4 2025.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.